// App-Quantinova.ai

3743 : Long-Term Anti-Leukemic Activity of Ponatinib in Patients with Philadelphia Chromosome-Positive Leukemia: Updated Results from an Ongoing Phase 1 Study

Researchers

Presenter

  • Jorge E. Cortes

Principal Investigators

  • Hagop M. Kantarjian

  • Victor M. Rivera

  • Tim Clackson

  • Christopher D. Turner

  • Frank G Haluska

  • Brian J. Druker

  • Moshe Talpaz

  • Neil Shah

  • Dale Bixby

  • Michael J. Mauro

  • Ian W. Flinn

  • Thomas O'Hare

  • Simin Hu

  • David J. Dorer

Medical Centers

  • N/A

Locations

  • N/A

Companies

  • ARIAD Pharmaceutical

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Acute lymphoblastic leukemia

  • Chronic Myelogenous Leukemia

  • Hematological malignancies

  • Thrombocytopenia

  • Pancreatitis

  • Neutropenia

Biomarkers

  • Breakpoint Cluster Region

  • Cluster of Differentiation 206

Drug/Treatment

  • Nilotinib

  • Ponatinib

  • dasatinib

  • Imatinib

  • IkT001

  • L-Tyrosine

  • lipase

Outcome

  • N/A

Study Design

  • open label

  • double blind/blinded

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved